Full Text View
Tabular View
No Study Results Posted
Related Studies
Prostate Cancer Intervention Versus Observation Trial (PIVOT):A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer
This study is ongoing, but not recruiting participants.
First Received: December 29, 2000   Last Updated: October 8, 2009   History of Changes
Sponsor: Department of Veterans Affairs
Collaborators: Agency for Healthcare Research and Quality (AHRQ)
National Cancer Institute (NCI)
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00007644
  Purpose

Radical prostatectomy provides potentially curative removal of the cancer. However, it subjects patients to the morbidity and mortality of the surgery and may be neither necessary nor effective. Expectant management does not offer potential cure. However, it provides palliative therapy for symptomatic or metastatic disease progression, avoids potentially excessive and morbid interventions in asymptomatic patients, and emphasizes management approaches for focus on relieving symptoms while minimizing therapeutic complications.

The primary objective of this study is to determine which of two strategies is superior for the management of clinically localized CAP: 1) radical prostatectomy with early aggressive intervention for disease persistence or recurrence, 2) expectant management with reservation of therapy for palliative treatment of symptomatic or metastatic disease progression. Outcomes include total mortality, CAP mortality, disease free and progression free survival, morbidity, quality of life, and cost effectiveness.


Condition Intervention Phase
Prostate Cancer
Procedure: Radical prostatectomy
Procedure: Expectant management with palliative therapy
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: CSP #407 - Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • All Cause Mortality [ Time Frame: Annual ] [ Designated as safety issue: No ]

Enrollment: 731
Study Start Date: June 1994
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
Radical Prostatectomy
Procedure: Radical prostatectomy
Surgical removal of the prostate
2: No Intervention
Watchful Waiting
Procedure: Expectant management with palliative therapy
palliative therapy for symptomatic or metastatic disease progression

Detailed Description:

Primary Hypothesis: To determine whether radical prostatectomy or expectant management is more effective in reducing mortality and extending life.

Secondary Hypothesis: To determine which treatment strategy is superior in terms of prostate specific cancer mortality, quality of life, occurrence or recurrence of symptoms and need for cancer treatment.

Intervention: 1) Radical prostatectomy, plus intervention for evidence of disease persistence or recurrence, 2) Expectant management with palliative therapy reserved for symptomatic or metastatic disease progression.

Primary Outcomes: All cause mortality.

Study Abstract: Cancer of the prostate (CAP) is the most common nondermatologic and the second most frequent cause of cancer deaths in men. No cure is currently possible for disseminated disease. Cancer confined to the prostate is believed to be curable, with the most frequently recommended therapy being surgical extirpation of the tumor with radical prostatectomy. However, despite increasing cancer detection and aggressive surgical treatment, population-based mortality rates from prostate cancer have not decreased, neither nationally nor in states with high rates of radical prostatectomy. Existing evidence does not demonstrate the superiority of this procedure compared to expectant management in the treatment of localized prostate cancer. Data from case series suggest that either treatment approach provides equivalent all-cause as well as prostate cancer specific mortality. The only randomized trial was limited by a small sample size but the results favored expectant management.

Radical prostatectomy provides potentially curative removal of the cancer. However, it subjects patients to the morbidity and mortality of the surgery and may be neither necessary nor effective. Expectant management does not offer potential cure. However, it provides palliative therapy for symptomatic or metastatic disease progression, avoids potentially excessive and morbid interventions in asymptomatic patients, and emphasizes management approaches for focus on relieving symptoms while minimizing therapeutic complications.

The primary objective of this study is to determine which of two strategies is superior for the management of clinically localized CAP: 1) radical prostatectomy with early aggressive intervention for disease persistence or recurrence, 2) expectant management with reservation of therapy for palliative treatment of symptomatic or metastatic disease progression. Outcomes include total mortality, CAP mortality, disease free and progression free survival, morbidity, quality of life, and cost effectiveness.

  Eligibility

Ages Eligible for Study:   up to 75 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with clinically localized CAP
  • Diagnosis of Prostate Cancer within previous 6 months
  • Age 75 years or younger

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00007644

  Show 31 Study Locations
Sponsors and Collaborators
Investigators
Study Chair: Timothy James Wilt, MD MPH Minneapolis Veterans Affairs Medical Center
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs ( Wilt, Timothy - Study Chair )
Study ID Numbers: 407
Study First Received: December 29, 2000
Last Updated: October 8, 2009
ClinicalTrials.gov Identifier: NCT00007644     History of Changes
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
cancer of the prostate (CAP)
cancer treatment
chronic diseases
expectant management
genitourinary
prostate
prostate specific cancer mortality
radical prostatectomy

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on November 25, 2009